Russo Suzanne, Jain Anshu K, Saif Muhammad Wasif
Department of Radiation Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36532, USA.
JOP. 2012 Mar 10;13(2):139-42.
Substantial controversy remains regarding the optimal adjuvant treatment for patients with resectable pancreatic adenocarcinoma. Despite improvements in radiation techniques, systemic therapies, and incorporation of targeted agents, the 5-year survival rates for early stage patients remains less than 25% and the optimal adjuvant treatment approach remains unclear. Here we summarize the data presented at the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding controversial issues surrounding the role, timing, and selection of patients for adjuvant chemoradiation strategies following curative resection for pancreatic adenocarcinoma. (Abstracts #301, #333, and #206).
对于可切除的胰腺腺癌患者的最佳辅助治疗，仍存在大量争议。尽管放射技术、全身治疗以及靶向药物的应用有所改进，但早期患者的5年生存率仍低于25%，最佳辅助治疗方法仍不明确。在此，我们总结了在2012年美国临床肿瘤学会（ASCO）胃肠道癌症研讨会上展示的数据，这些数据涉及胰腺腺癌根治性切除术后辅助放化疗策略的作用、时机和患者选择等争议性问题。（摘要#301、#333和#206）
Zotero 插件